Join Growin Stock Community!

Outset medical, inc.OM.US Overview

US StockHealthcare
(No presentation for OM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OM AI Insights

OM Overall Performance

OM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OM Recent Performance

3.88%

Outset medical, inc.

1.63%

Avg of Sector

0.63%

S&P500

OM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OM Key Information

OM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OM Profile

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Price of OM

OM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.53
PB Ratio
0.50
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
39.13%
Net Margin
-68.34%
Revenue Growth (YoY)
5.09%
Profit Growth (YoY)
21.24%
3-Year Revenue Growth
-3.38%
3-Year Profit Growth
32.37%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.46
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.53
PB Ratio
0.50
Price-to-FCF
-
Gross Margin
39.13%
Net Margin
-68.34%
Revenue Growth (YoY)
5.09%
Profit Growth (YoY)
21.24%
3-Year Revenue Growth
-3.38%
3-Year Profit Growth
32.37%
  • When is OM's latest earnings report released?

    The most recent financial report for Outset medical, inc. (OM) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OM's short-term business performance and financial health. For the latest updates on OM's earnings releases, visit this page regularly.

  • What is the operating profit of OM?

    According to the latest financial report, Outset medical, inc. (OM) reported an Operating Profit of -17.63M with an Operating Margin of -61.05% this period, representing a growth of 19.35% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is OM's revenue growth?

    In the latest financial report, Outset medical, inc. (OM) announced revenue of 28.87M, with a Year-Over-Year growth rate of -2.01%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OM have?

    As of the end of the reporting period, Outset medical, inc. (OM) had total debt of 101.25M, with a debt ratio of 0.38. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OM have?

    At the end of the period, Outset medical, inc. (OM) held Total Cash and Cash Equivalents of 38.84M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does OM go with three margins increasing?

    In the latest report, Outset medical, inc. (OM) did not achieve the “three margins increasing” benchmark, with a gross margin of 42.4%%, operating margin of -61.05%%, and net margin of -67.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess OM's profit trajectory and future growth potential.

  • Is OM's EPS continuing to grow?

    According to the past four quarterly reports, Outset medical, inc. (OM)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OM?

    Outset medical, inc. (OM)'s Free Cash Flow (FCF) for the period is -9.74M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 41.06% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of OM?

    The latest valuation data shows Outset medical, inc. (OM) has a Price-To-Earnings (PE) ratio of -0.76 and a Price/Earnings-To-Growth (PEG) ratio of -0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.